

Heidi Bruty, MD
Child, Adolescent and Adult Psychiatric Medicine

Previous Employment

Assistant Professor
UT Southwestern Medical School
Department of Child and Adolescent Psychiatry
July 2010 – March 2014

Medical Director, Psychiatry In-Patient Services
Children's Medical Center, Dallas, Texas
November 2011 - March 2014

Assistant Medical Director, Psychiatry Consult Liason
Children's Medical Center, Dallas, Texas
July 2010 – November 2011

Staff Child & Adolescent Psychiatrist
Dallas Metrocare Services, Dallas Texas
July 2009 – July 2010

Assistant Professor
University of South Florida College of Medicine
Department of Psychiatry and Behavioral Medicine
Division, Child and Adolescent Psychiatry
February 2007 – November 2008

Child & Adolescent Psychiatry Fellowship

Child & Adolescent Psychiatry Fellowship
Department of Psychiatry and Behavioral Medicine
University of South Florida College of Medicine
Tampa, Florida
September 2004-November 2006

General Adult Psychiatry Residency

Department of Psychiatry and Behavioral Medicine
University of South Florida College of Medicine
Tampa, Florida
July 2001- September 2004

Medical Education

Doctor of Medicine
University of South Florida College of Medicine
Tampa, Florida
1997-2001

Undergraduate Education

University of South Florida
Post-Baccalaureate Studies
Tampa, Florida
1996-1997

Emory University

Bachelor of Arts
Atlanta, Georgia
1992-1996

Certifications

Diplomate of Board of Child & Adolescent Psychiatry, November 2008
Diplomate of Board of Psychiatry and Neurology, June 2007

Honors and Awards

Chief Resident, Child and Adolescent Psychiatry, 2005-2006
Ginsberg Fellowship with Group for the Advancement of Psychiatry,
2002-2004
AACAP Eli Lilly Outstanding General Psychiatry Resident Award, 2002
University of South Florida, Department of Psychiatry and
Behavioral Medicine, Chairman's Award for Scholarly and
Creative Activity, 2002
Outstanding Student in Psychiatry, University of South Florida
College of Medicine, 2000-2001
Award for Clinical Excellence in Psychiatry Clerkship, University
of South Florida College of Medicine, 1999-2000
Magna Cum Laude, Emory University, 1996
Phi Beta Kappa, Emory University, 1995

Publications

Bruty HR, Emslie GJ, Croarkin P. Novel (Atypical) Antidepressants. Pharmacotherapy of Child and Adolescent Psychiatric Disorders, Third Edition. Rosenberg D and Gershon S (eds). John Wiley & Sons, Ltd., 2012

Power P, Bruty, H: Pharmacotherapy for Eating Disorders and Obesity, Child and Adolescent Psychiatric Clinics of North America, 2008;18: 31-47

Berman EM, Heru AM, Grunebaum H, Rolland J, Wood B, Bruty H: Family Skills for General Psychiatry Residents: Meeting ACGME Core Competency Requirements, Academic Psychiatry, 2006; 30(1): 69-78

Brauer HR, Nowicki PW, Catalano G, Catalano MC: Panic Attacks Associated with Citalopram, Southern Medical Journal, 2002; 95(9): 1088-1089

Smith AG, Brauer HR, Catalano G, Catalano MC: Topiramate Overdose: A Case Report and Literature Review, *Epilepsy & Behavior*, 2001; 2: 603-607

Research Activities

Sub-Investigator, Forest, "Open Label Long-Term Study of Escitalopram in Children 7 to 11 Years of Age with Major Depressive Disorder (SCT MD 55), 2011

Principal Investigator, GlaxoSmithKline, "The Evaluation of LAMCITAL as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10-17 Years of Age (SCA 102833), 2008

Principal Investigator, Boehringer Ingelheim, "An open-label, flexible dose, follow-up study to evaluate safety and efficacy of oral Pramipexole (0.0625-0.5 mg/day) for 24 weeks in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette's Disorder according to DSM-IV criteria and who have completed the double-blind phase of either study 248.641 or 248.644," 2008

Principal Investigator, Boehringer Ingelheim, "A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.125-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-17 inclusive) diagnosed with Tourette's Disorder according to DSM-IV criteria," 2008

Sub-Investigator, Bristol Myers Squibb, "Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study with Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents with Autism Disorder," 2007-2008

Sub-Investigator, Bristol Myers Squibb, "A 52 Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder," 2007-2008

Professional Memberships

American Psychiatric Association
American Academy of Child and Adolescent Psychiatry
American Medical Association